{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:24:32Z","timestamp":1752549872543,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The study received funding from Basic and Applied Basic Research Foundation of GuangDong Province","award":["2020A1515110923"],"award-info":[{"award-number":["2020A1515110923"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02711-z","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:48:23Z","timestamp":1748242103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study"],"prefix":"10.1007","volume":"16","author":[{"given":"Mengyuan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"4","key":"2711_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"JA Ajani","year":"2023","unstructured":"Ajani JA, Damico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi J, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, Mcmillian NR, Pluchino LA. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393\u2013422.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2711_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semradonc.2006.09.007","volume":"17","author":"JR Siewert","year":"2007","unstructured":"Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38\u201344.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"2711_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00595-019-01878-7","volume":"50","author":"M Watanabe","year":"2020","unstructured":"Watanabe M, Otake R, Kozuki R, Toihata T, Takahashi K, Okamura A, Imamura Y. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12\u201320.","journal-title":"Surg Today"},{"issue":"10","key":"2711_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaoncol.2021.2705","volume":"7","author":"Y Ji","year":"2021","unstructured":"Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L, Li J, Tao H, Xia J, Yang H, Huang J, Bao Y, Du D, Liu D, Wang X, Li C, Yang X, Zeng M, Liu Z, Zheng W, Pu J, Chen J, Hu W, Li P, Wang J, Xu Y, Zheng X, Chen J, Wang W, Tao G, Cai J, Zhao J, Zhu J, Jiang M, Yan Y, Xu G, Bu S, Song B, Xie K, Huang S, Zheng Y, Sheng L, Lai X, Chen Y, Cheng L, Hu X, Ji W, Fang M, Kong Y, Yu X, Li H, Li R, Shi L, Shen W, Zhu C, Lv J, Huang R, He H, Chen M. Efficacy of concurrent chemoradiotherapy with s-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol. 2021;7(10):1459\u201366.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2711_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13014-021-01788-4","volume":"16","author":"C Pottgen","year":"2021","unstructured":"Pottgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jockel KH, Lax H, Stuschke M. Dose-escalated radiotherapy with PET\/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3\/T4) squamous cell cancer of the esophagus: mature results of a phase I\/II trial. Radiat Oncol. 2021;16(1):59.","journal-title":"Radiat Oncol"},{"issue":"5","key":"2711_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94\u201305) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2711_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","volume":"26","author":"J Tepper","year":"2008","unstructured":"Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2711_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/dote.12215","volume":"28","author":"E Versteijne","year":"2015","unstructured":"Versteijne E, van Laarhoven HW, van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI, Hulshof MC. Definitive chemoradiation for patients with inoperable and\/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus. 2015;28(5):453\u20139.","journal-title":"Dis Esophagus"},{"key":"2711_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2022.06.015","volume":"174","author":"D Qian","year":"2022","unstructured":"Qian D, Chen X, Shang X, Wang Y, Tang P, Han D, Jiang H, Chen C, Zhao G, Zhou D, Cao F, Er P, Zhang W, Li X, Zhang T, Zhang B, Guan Y, Wang J, Yuan Z, Yu Z, Wang P, Pang Q. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: a phase II random. Radiother Oncol. 2022;174:1\u20137.","journal-title":"Radiother Oncol"},{"issue":"10","key":"2711_CR10","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/cncr.26586","volume":"118","author":"J Welsh","year":"2012","unstructured":"Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118(10):2632\u201340.","journal-title":"Cancer"},{"issue":"1","key":"2711_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2012.10.022","volume":"106","author":"MB Meng","year":"2013","unstructured":"Meng MB, Jiang XD, Deng L, Na FF, He JZ, Xue JX, Guo WH, Wen QL, Lan J, Mo XM, Lang JY, Lu Y. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence. Radiother Oncol. 2013;106(1):130\u20137.","journal-title":"Radiother Oncol"},{"issue":"21","key":"2711_CR12","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF. Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2711_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","volume":"77","author":"M Nordsmark","year":"2005","unstructured":"Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy International multi-center study. Radiother Oncol. 2005;77(1):18\u201324.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2711_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2397","volume":"8","author":"MW Dewhirst","year":"2008","unstructured":"Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8(6):425\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2711_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40487-017-0055-1","volume":"6","author":"K Li","year":"2018","unstructured":"Li K, Shi M, Qin S. Current status and study progress of recombinant human endostatin in cancer treatment. Oncol Ther. 2018;6(1):21\u201343.","journal-title":"Oncol Ther"},{"issue":"4","key":"2711_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/theoncologist.2019-0119","volume":"24","author":"W Li","year":"2019","unstructured":"Li W, Chen P, Zhang N, Song T, Wu S. Endostatin and oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase II study. Oncologist. 2019;24(4):461-e136.","journal-title":"Oncologist"},{"issue":"5","key":"2711_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4251\/wjgo.v6.i5.112","volume":"6","author":"KJ Napier","year":"2014","unstructured":"Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112\u201320.","journal-title":"World J Gastrointest Oncol"},{"key":"2711_CR18","unstructured":"NCCN CLinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal and esophagogastric junction cancers. Fort Washington: National Comprehensive Cancer Network; Version 2.2019; 2019."},{"issue":"1","key":"2711_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13014-022-02078-3","volume":"17","author":"H Li","year":"2022","unstructured":"Li H, Fang Y, Gu D, Du M, Zhang Z, Sun L, Zhou G, Ye J. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial. Radiat Oncol. 2022;17(1):105.","journal-title":"Radiat Oncol"},{"key":"2711_CR20","doi-asserted-by":"publisher","first-page":"3834040","DOI":"10.1155\/2021\/3834040","volume":"2021","author":"X Pan","year":"2021","unstructured":"Pan X, Liao M, Ma H, Jiang X, Huang H, Wei M, Li Q. Chemoradiotherapy and increased prescription dose in esophageal squamous cell cancer: a retrospective study. Biomed Res Int. 2021;2021:3834040.","journal-title":"Biomed Res Int"},{"issue":"Supplement","key":"2711_CR21","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.4103\/jcrt.JCRT_404_20","volume":"18","author":"S Ghosh-Laskar","year":"2022","unstructured":"Ghosh-Laskar S, Mummudi N, Kumar S, Chandre M, Mishra S, Tibdewal A, Agarwal JP, Patil V, Noronha V, Prabash K, Patil P, Jiwnani S, Karimundackal G, Pramesh CS. Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus. J Cancer Res Ther. 2022;18(Supplement):S285\u201392.","journal-title":"J Cancer Res Ther"},{"key":"2711_CR22","volume-title":"Prescribing, recording and reporting photon beam therapy (report 62) (supplement to icru report 50)","author":"ICRU","year":"1999","unstructured":"ICRU. Prescribing, recording and reporting photon beam therapy (report 62) (supplement to icru report 50). Bethesda: ICRU; 1999."},{"key":"2711_CR23","unstructured":"C.S.o.C.O. (CSCO). Guidelines of Chinese Society of Clinical Oncology (CSCO) esophageal cancer; 2024."},{"issue":"8","key":"2711_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/dote.12540","volume":"29","author":"TW Rice","year":"2016","unstructured":"Rice TW, Ishwaran H, Blackstone EH, Hofstetter WL, Kelsen DP, Apperson-Hansen CI. Worldwide Esophageal cancer collaboration, recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th AJCC\/UICC staging manuals. Dis Esophagus. 2016;29(8):913\u20139.","journal-title":"Dis Esophagus"},{"key":"2711_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"11","key":"2711_CR26","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","volume":"3","author":"M Suntharalingam","year":"2017","unstructured":"Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, Chakravarthy AB, Anker CJ, Thakrar H, Horiba N, Dubey A, Greenberger JS, Raben A, Giguere J, Roof K, Videtic G, Pollock J, Safran H, Crane CH. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520\u20138.","journal-title":"JAMA Oncol"},{"issue":"11","key":"2711_CR27","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/1759-7714.12827","volume":"9","author":"S Zhou","year":"2018","unstructured":"Zhou S, Zuo L, He X, Pi J, Jin J, Shi Y. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed\/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: a retrospective comparison with standard chemotherapy. Thorac Cancer. 2018;9(11):1354\u201360.","journal-title":"Thorac Cancer"},{"issue":"2","key":"2711_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ph16020219","volume":"16","author":"C Cunningham","year":"2023","unstructured":"Cunningham C, Bolcaen J, Bisio A, Genis A, Strijdom H, Vandevoorde C. Recombinant endostatin as a potential radiosensitizer in the treatment of non-small cell lung cancer. Pharmaceuticals (Basel). 2023;16(2):219.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 2","key":"2711_CR29","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/S0049-3848(10)70014-1","volume":"125","author":"F Elice","year":"2010","unstructured":"Elice F, Rodeghiero F. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res. 2010;125(Suppl 2):S55\u20137.","journal-title":"Thromb Res"},{"issue":"5","key":"2711_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa YI. CheckMate 648 trial, nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"24","key":"2711_CR31","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, I.M.S. Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02711-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T06:48:25Z","timestamp":1748242105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02711-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center and individual consent for this retrospective analysis was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plans of our research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"925"}}